PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce ...
A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late ...
The oral drug reduced DUX4 in FSHD patient muscle cells and increased lean mass and muscle power in a human study ...
New silica-based chromatography media helps biopharmaceutical manufacturers achieve demanding purity targets while supporting ...
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 ...
These honors underscore Cepheid's continued focus on helping healthcare providers deliver A Better Way through timely ...
Granata Bio Corporation, a biopharmaceutical company dedicated to advancing reproductive medicine, today announced the ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the appointment of Chadi ...
Antogen, Inc., a biotechnology company pioneering next-generation personalized diagnostics through immunopeptidomics, today ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of ...
New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results